Opiant Pharmaceuticals (OPNT) stock price, revenue, and financials

Opiant Pharmaceuticals market cap is $32.2 m, and annual revenue was $40.52 m in FY 2019

$32.2 M

OPNT Mkt cap, 16-Oct-2020

$6.3 M

Opiant Pharmaceuticals Revenue Q2, 2020
Opiant Pharmaceuticals Net income (Q2, 2020)-216.2 K
Opiant Pharmaceuticals EBIT (Q2, 2020)-231.6 K
Opiant Pharmaceuticals Cash, 30-Jun-202030.5 M
Opiant Pharmaceuticals EV2.2 M

Opiant Pharmaceuticals Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

18.4m14.0m40.5m

Revenue growth, %

(24%)

Cost of goods sold

Gross profit

40.5m

Gross profit Margin, %

100%

Sales and marketing expense

1.7m213.9k611.6k

R&D expense

3.2m8.5m9.1m

General and administrative expense

6.5m11.3m12.2m

Operating expense total

11.4m35.2m29.6m

EBIT

7.1m(21.2m)10.9m

EBIT margin, %

38%(152%)27%

Interest expense

20.0k437.7k

Interest income

20.0k144.7k

Pre tax profit

7.1m(21.1m)11.4m

Income tax expense

550.5k51.3k(177.2k)

Net Income

6.6m(21.2m)11.6m

Opiant Pharmaceuticals Balance Sheet

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.6k47.4k25.0k2.2k151.7k609.9k323.7k420.4k180.8k1.1m1.1m1.3m455.2k1.3m2.4m1.2m12.9m9.7m5.9m11.3m11.2m24.8m23.8m23.9m23.2m32.2m30.5m

Accounts Receivable

699.1k3.0m2.0m4.3m16.1m4.2m

Prepaid Expenses

534.5k729.0k737.0k560.0k346.0k522.0k493.0k940.0k1.0m

Current Assets

12.6k47.4k25.0k2.2k151.7k639.7k336.5k424.7k222.5k1.7m1.1m1.4m473.0k1.3m2.4m2.0m13.0m9.8m6.8m13.7m14.8m29.3m26.2m28.8m40.2m37.4m38.7m

PP&E

6.4k5.6k4.6k3.7k2.0k2.0k55.0k274.0k199.1k233.4k

Total Assets

38.3k72.8k50.2k26.4k175.6k663.2k359.2k447.2k244.7k1.7m1.1m1.4m493.0k1.3m2.5m2.0m13.0m9.8m6.8m13.8m14.8m29.3m26.3m28.8m41.4m38.3m39.4m

Accounts Payable

27.4k41.7k111.2k58.8k60.5k71.9k24.3k13.1k19.1k71.8k77.6k76.0k107.1k35.2k206.8k641.5k756.2k1.4m1.3m3.5m2.2m1.3m1.5m1.1m2.0m1.5m1.4m

Short-term debt

3.6k3.9k4.7k5.0k5.2k6.0k6.3k6.7k7.4k7.7k8.0k165.0k9.1k9.4k499.9k476.9k

Current Liabilities

1.5m1.1m1.5m2.1m2.3m2.5m3.8m3.9m4.1m4.8m5.2m3.1m4.3m5.7m4.3m3.7m9.5m8.8m9.4m4.3m5.1m

Long-term debt

358.0k

Non-Current Liabilities

2.4m2.2m2.1m402.0k358.0k131.0k34.8k

Total Debt

3.6k3.9k25.0k5.0k5.2k6.0k6.3k6.7k7.4k7.7k8.0k165.0k9.1k9.4k358.0k499.9k476.9k

Total Liabilities

269.7k368.1k533.8k865.5k1.2m1.2m2.2m2.1m2.5m5.3m7.1m8.3m9.7m6.2m6.2m7.1m7.0m5.5m6.8m7.8m6.4m4.1m9.5m8.8m9.8m4.5m5.1m

Common Stock

92.0k104.3k117.3k130.6k132.8k145.8k168.4k178.2k178.2k179.0k1.8k1.8k1.9k1.9k2.0k2.0k2.0k2.0k2.0k3.0k3.0k4.0k4.0k4.0k4.0k4.3k4.3k

Additional Paid-in Capital

15.9m20.4m21.7m24.1m24.4m26.0m34.6m39.7m39.7m43.3m43.9m44.9m55.3m55.6m56.4m56.7m57.1m58.5m60.3m68.5m72.3m90.1m92.9m94.6m95.5m98.6m99.3m

Retained Earnings

(47.1m)(49.9m)(51.7m)(64.5m)(60.5m)(60.1m)(61.8m)(51.1m)(54.3m)(60.2m)(62.6m)(64.0m)(64.9m)(76.2m)(74.6m)(63.9m)(64.5m)(64.7m)

Total Equity

(231.4k)(295.3k)(483.7k)(839.1k)(1.0m)(526.1k)(1.8m)(1.7m)(2.3m)(3.6m)(6.0m)(6.9m)(9.2m)(4.9m)(3.7m)(5.1m)6.0m4.3m46.0k5.9m8.4m25.2m16.8m20.1m31.6m33.8m34.3m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0.1 x0.1 x

Financial Leverage

-0.2 x-0.2 x-0.1 x0 x-0.2 x-1.3 x-0.2 x-0.3 x-0.1 x-0.5 x-0.2 x-0.2 x-0.1 x-0.3 x-0.7 x-0.4 x2.2 x2.3 x147.8 x2.3 x1.8 x1.2 x1.6 x1.4 x1.3 x1.1 x1.1 x

Opiant Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(12.4m)(4.7m)(11.5m)(7.0m)(7.8m)1.4m(21.2m)11.6m

Depreciation and Amortization

1.4k1.4k1.4k1.4k2.4k2.1k2.6k60.8k

Accounts Receivable

(312.5k)(7.9m)7.2m(2.7m)

Accounts Payable

(48.6k)(14.7k)159.8k114.9k(174.9k)1.1m(1.9m)361.2k

Cash From Operating Activities

(1.1m)(747.3k)(1.0m)(4.2m)(915.3k)(3.8m)(523.0k)4.1m

Purchases of PP&E

(7.5k)(302.5k)

Cash From Investing Activities

(7.5k)(302.5k)

Cash From Financing Activities

1.1m1.3m661.5k4.4m2.0m5.1m17.0m2.6m

Net Change in Cash

(31.4k)578.2k(343.9k)179.4k1.0m1.2m16.5m6.4m

Interest Paid

6.7k257.8k78.9k

Income Taxes Paid

619.2k174.0k800.0

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.7m)(9.3m)(10.8m)(1.1m)(1.6m)(2.7m)(1.7m)(6.8m)(7.3m)(775.3k)(3.6m)(5.4m)(11.1m)(7.1m)(6.7m)(600.6k)10.0m6.9m(5.6m)(9.3m)(10.7m)(11.7m)(1.7m)(158.0k)10.5m(1.7m)(1.9m)

Depreciation and Amortization

254.0508.0762.0343.0686.01.0k419.0686.0954.0344.0687.01.0k343.0686.01.2k1.3k2.6k3.9k1.0k1.0k2.0k2.0k5.0k29.0k37.3k60.4k

Accounts Receivable

(386.6k)312.5k312.5k3.8m10.0m8.7m7.6m2.5m144.0k(11.6m)3.0m932.1k

Accounts Payable

(77.5k)(63.1k)6.4k3.3k5.0k16.4k(16.4k)(27.7k)(21.7k)(128.9k)(123.0k)(124.6k)(208.4k)(280.2k)(108.6k)500.9k615.6k1.3m685.0k221.0k(1.7m)(2.5m)349.0k(59.0k)819.0k144.8k113.6k

Cash From Operating Activities

(510.1k)(575.3k)(747.7k)(205.7k)(372.9k)(569.7k)(274.9k)(431.7k)(671.3k)(974.0k)(2.4m)(3.1m)(748.2k)(356.2k)732.3k(296.8k)11.6m8.4m(970.0k)2.2m678.0k(305.0k)(1.4m)(2.1m)(2.8m)830.0k(816.6k)

Purchases of PP&E

(6.5k)(59.0k)(302.0k)(50.9k)

Cash From Investing Activities

(6.5k)(59.0k)(302.0k)6.6k(50.9k)

Short-term Borrowings

(165.0k)(165.0k)

Cash From Financing Activities

470.9k570.9k720.9k187.5k504.2k1.2m253.5k253.5k1.9m3.2m4.2m769.2k1.2m1.2m(165.0k)(165.0k)1.0m2.5m17.0m601.0k1.4m1.7m685.1k685.1k

Net Change in Cash

(39.2k)(4.4k)(26.8k)(18.2k)131.3k589.5k(274.9k)(178.2k)(417.8k)892.9k806.1k1.1m21.0k847.3k1.9m(296.8k)11.4m8.2m(970.0k)3.2m3.1m16.7m(846.0k)(697.0k)(1.4m)1.2m(478.1k)

Interest Paid

13.5k16.5k6.7k6.7k257.8k125.5k125.5k139.0k78.9k78.9k4.8k4.8k

Income Taxes Paid

39.0k

Opiant Pharmaceuticals Ratios

USDQ1, 2012

Financial Leverage

-0.2 x